Narcolepsy | Treatment Algorithms | Claims Data Analysis | US | 2020

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy, which include excessive daytime sleepiness and cataplexy. Despite many available pharmacological treatments, a large proportion of patients have inadequate control of their narcolepsy symptoms. Given that the narcolepsy treatment is highly individualized and complex, it is essential to understand the use of current therapies in the nuanced narcolepsy treatment algorithm ahead of anticipated product launches. Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies in narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed narcolepsy patients?
• How have branded agents such as pitolisant (Harmony Biosciences’ Wakix), solriamfetol (Jazz Pharmaceuticals’ Sunosi), and sodium oxybate (Jazz Pharmaceuticals’ Xyrem) been integrated into the treatment algorithm, and what is their source of business?
• What percentage of narcolepsy patients receive drug therapy within four years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within four years of diagnosis?
• What percentage of narcolepsy patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Armodafinil, atomoxetine, modafinil, Sunosi, Vyvanse, Wakix, Xyrem

Key companies covered: Eli Lilly, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, Teva

Key analysis provided:

• Brand / therapy usage across longitudinal patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Combination therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flowcharts.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.